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Abstract
Introduction: In an ageing population the prevalence of osteoporosis and chronic respiratory diseases is expected to increase 
in the near future. Interestingly, several forms of corticosteroids, drugs implicated in osteoporosis pathogenesis, are prescribed 
to respiratory patients without taking into consideration their age and risk for osteoporotic fractures. The aim of this study was 
to investigate the risk for hip fracture of the elder individuals who are taking corticosteroids for respiratory disease, including 
inhalers.
Material and methods: Data on incident hip fractures were collected through the active follow-up for all individuals participating 
in the Greek segment of the European Prospective Investigation into Cancer and Nutrition (EPIC-Greece) study who were 60 years 
or older at recruitment and reported “a doctor’s diagnosis” of respiratory disease. Socio-demographic, life-style, health status data 
and use of corticosteroids were recorded from the baseline and follow-up questionnaires. Cox regression models were applied to 
estimate hazard ratios (HRs) adjusting for relevant confounders.
Results: We observed an increase in hip fracture risk with corticosteroid intake overall (HR: 1.68, 95% CI: 0.85–3.34). Increased 
risk persisted when we restricted our analysis to participants taking any form of corticosteroids for obstructive lung disease (HR: 
1.40, 95% CI: 0.64–3.06) and to those using only inhalers (HR: 1.58, 95% CI: 0.71–3.50). However, these positive associations did 
not reach the nominal level of significance probably due to the small number of participants with hip fractures during follow-up.
Conclusion: Hip fracture risk should be taken into consideration when recommending corticosteroids to the elder respiratory 
patients, including inhalers.
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Introduction
Older age is a well established risk factor for 
fractures. Among them hip fracture is a serious 
cause of disability and mortality in the elderly 
populations [1, 2]. Certain drugs, especially cor-
ticosteroids have been implicated to osteoporotic 
fractures’ pathogenesis [3]. Respiratory patients 
very often receive several forms of corticoste-
roids (orally, injected or inhalants) either con-
tinuously or intermittently and thus, are at high 
risk for osteoporotic fractures [4]. The current 
evidence is less clear on the impact of inhaled 
corticosteroids (ICSs) currently used by patients 
having obstructive lung diseases [5]. According 
to a meta-analysis the overall prevalence of osteo-
porosis in chronic obstructive pulmonary disease 
(COPD) is 35% [6]. However, osteoporosis in this 
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population is poorly identified and undertreated 
due to lack of specific guidelines. Needless to say 
that even more limited are the data concerning 
elderly populations.
Since the proportion of the elderly in the 
population is growing and COPD is also expected 
to rise and be one of the main causes of death by 
2020 [7] the incidence of fractures is expected to 
significantly increase in the future. In an ageing 
population to keep older active for as long as 
possible it is necessary to recognize risk factors 
related to frailty, determine their distribution and 
implement prevention or optimize treatment. 
In the present study, conducted in the con-
text of the Greek segment of the European Pro-
spective Investigation into Cancer and Nutrition 
(EPIC-Greece) study, we investigate the risk for 
hip fracture of elder individuals who are taking 
corticosteroids for a respiratory disease.
Material and methods
Study design-subjects
The study population consisted of all individ-
uals participating in the EPIC-Greece study who 
were 60 years or older at recruitment and report-
ed “a doctor’s diagnosis” of respiratory disease. 
Participants who developed respiratory disease 
during follow-up were also included in the study. 
EPIC is a prospective study conducted in 23 
research centers across 10 European countries 
aiming to determine the incidence of and mortality 
from cancer and other diseases in relation to several 
individual characteristics, biologic, dietary, lifestyle 
and environmental factors [8–11]. In Greece, a total 
of 28,572 (men and women) apparently healthy 
volunteers aged 20-86 years were recruited from all 
regions of the country during 1994–1999. Among 
them 9,863 were aged ≥ 60 years. All procedures 
were in line with the Helsinki declaration for hu-
man rights, all volunteers signed informed consent 
forms, and the study protocol was approved by 
ethical committees at the International Agency for 
Research on Cancer and at the National and Kapo-
distrian University of Athens, School of Medicine. 
Sociodemographic, dietary, lifestyle and health data 
including “a doctor’s diagnosed” disease, history 
of smoking and physical activity were obtained at 
enrollment by pre-coded questionnaires adminis-
tered to each participant by specially trained inter-
viewers. Anthropometry measurements were also 
undertaken by using standardized procedures [12]. 
During the study period, participants’ vital status 
was ascertained by active follow up and information 
from mortality registries. 
In the present study participants were select-
ed based on age and self-reporting of “a doctor’s 
diagnosis” of respiratory disease (ICD-10-CM 
diagnosis codes J00-J99). Individuals using in-
halers (short or long acting b2 adrenergic and/
or anticholinergics and/or corticosteroids) with-
out ever having reported in the questionnaires 
“a doctor’s diagnosis” of respiratory disease were 
also included as having “possible obstructive 
pulmonary disease”. Finally, among participants 
those reporting chronic obstructive pulmonary 
disease (J44), asthma (J45) and emphysema (J43) 
were identified in order to perform additional 
subgroup analyses.
Hip fractures
Data on incident hip fractures were collect-
ed through active follow-up using telephone 
interviews or mailed questionnaires, eliciting 
self-reported information. In a validation study 
conducted in Greece, 79% of self reported cases of 
incident hip fractures were medically confirmed 
[13]. If there was more than one hip fracture re-
corded for the same individual, only the first one 
was used in the analysis.
Corticosteroids use
Information on systemic use of plain corti-
costeroids (H02A, ATC classification system) as 
well as use of inhalants corticosteroid (R03AB) or 
corticosteroids in combination with adrenergics 
(R03AK) was recorded from the baseline and 
follow-up questionnaires.
Body mass index and physical activity
Body mass index (BMI) was derived as the 
ratio of weight in kilograms divided by the square 
of height in meters. 
The protocol we used to estimate physical 
activity for each participant has been described 
in detail in previous publications [14–15].
Analyses
In our analyses, to estimate hazard ratios 
(HRs) for hip fracture incidence, Cox regression 
was used adjusting for age, sex, educational level, 
BMI, physical activity and smoking status. For the 
participants with respiratory disease at baseline, 
the survival time was calculated from the date 
of enrollment at the study till the date of death 
(for those who died during the follow-up) or till 
the date of the last follow-up (for those who were 
alive at that time) or till the date of a hip fracture 
event (for those who faced a hip fracture event 
during the follow-up). For the participants that 
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developed a respiratory disease for the first time 
during follow-up, the date of entry for them in our 
analysis was assumed to be the date respiratory 
disease was first diagnosed. Subjects with missing 
values in variables included in the applied models 
were excluded from the analysis.
All analyses were carried out using the Stata 
Statistical Software, release 11 (StataCorp. 2009, 
StataCorp LP).
Results
A total of 2,487 elderly participants reporting 
“a doctor’s diagnosis” of respiratory disease was 
identified. During a median follow-up of 10.9 years 
and a total contribution of 24,587 person-years, 
 a total of 61 incident cases of hip fractures (51 
women and 10 men) were recorded. Age, BMI, 
physical activity and educational status were 
similar between participants having a hip fracture 
and those who did not have (Table 1).
Out of all the above participants 2.5% had 
at least one hip fracture whilst this percentage 
increased to 2.9% when we included only those 
reporting having obstructive lung disease. About 
10% of all study participants reported use of cor-
ticosteroids, mainly inhalants (77.2%), and 3.8% 
of them (overall) presented a hip fracture (5.9% 
and 3.4% under systemic use or use of inhalants 
respectively) (Table 1).
Corticosteroid intake increased hip fracture 
risk in all elderly participants reporting respi-
ratory disease (HR: 1.68, 95% CI: 0.85–3.34) as 
well as to those with obstructive lung disease 
(HR: 1.40, 95% CI: 0.64–3.06). Moreover, in-
crease in risk persisted when we restricted the 
analyses only to inhalant corticosteroids (HR: 
1.58, 95% CI: 0.71–3.50). However, in all cases 
the associations did not reach the nominal level 
of significance probably due to the small num-
ber of participants with hip fractures during 
the follow-up (Table 2). Furthermore, this small 
number of incident fractures did not allow us to 
perform further subgroup analyses to estimate 
the risk of hip fracture for each one of the obs-
tructive respiratory diseases (COPD, asthma or 
emphysema) separately.
Discussion
In this study performed in the context of 
EPIC-Greece study we observed an increase in 
hip fracture risk with corticosteroid intake (in-
halants included) in elderly participants with 
chronic respiratory disease. The increase in risk 
remained after restricting the analyses only to the 
elderly with obstructive lung disease. However, 
the above mentioned increase did not reach the 
nominal level of significance mainly due to the 
small number of participants with hip fractures 
during the follow-up. 
So far, to the best of our knowledge, studies 
relating risk of hip fractures in elder respiratory 
patients are lacking. Among these patients, those 
suffering from chronic obstructive lung disease 
mainly asthma or COPD often receive several 
forms of corticosteroids, drugs known to be im-
plicated in the pathogenesis of osteoporosis and 
fractures [3, 4]. The development of osteoporosis 
is a major concern with oral corticosteroids [16]. 
However, previous studies examining the impact 
of ICSs on bone mineral density (BMD) of patients 
with asthma provide conflicting results. Some of 
them have found significant BMD changes whilst 
in others ICS administration was not associated 
with BMD changes in asthmatics [17, 18]. Similar-
ly, mixed are the results from studies examining 
hip fracture risk in COPD patients and indicate 
that the effect may be dose dependent [19–21].
In the treatment of moderate or severe asthma 
corticosteroids are considered to be the mainstay 
(www.gina.org). However, the balance between 
risk and benefit concerning potential long term 
adverse events is not so clear for mild asthmatics, 
while there is lack of studies focusing on the el-
derly. In a study concerning patients with mild 
asthma but younger than 60 years, Tattersfield 
and coworkers report significant changes in bone 
density which were thought not to be clinically 
important in participants who use relatively low 
doses of ICS [18]. Another important issue that 
should also be considered in elderly patients are 
co-morbidities such as cardiovascular disease or 
left heart failure that may present with symptoms 
mimicking asthma leading thus to asthma over-
diagnosis and consequently overtreatment with 
several forms of corticosteroids. 
Chronic obstructive pulmonary disease is a ma-
jor cause of morbidity and mortality worldwide [22]. 
In Greece the prevalence of COPD among smokers 
is 8.4% [23]. Overtreatment of COPD mainly with 
corticosteroids is an international phenomenon 
occurring also in Greece and is more pronounced 
in early stage and stable disease [24–26]. It is es-
timated that 38.8% and 51.8% GOLD Groups A 
and B, respectively, use corticosteroids although 
these patients do not meet the recommendation 
criteria [27]. Furthermore, screening for and 
treating osteoporosis is not clinicians’ priority 
in this group of patients probably reflecting 
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Table 1. Characteristics of the elderly participants with respiratory disease in the EPIC-Greece study and distribution of 
corticosteroid use among them by hip fracture
All Hip fractures
(n = 2,487) No (n = 2,426) Yes (n = 61)
Age (years), mean (SD) 68.0 (5.2) 68.0 (5.1) 69.8 (5.0)
BMI (kg/m2), mean (SD) 29.8 (4.8) 29.8 (4.8) 29.0 (5.2)
Physical Activity*, mean (SD) 33.6 (4.7) 33.6 (4.8) 33.5 (3.5)
Education, n (%)
   Elementary 2,145 (86) 2,091 (86) 54 (89)
   High School-Lycee 235 (10) 230 (10) 5 (8)
   University 107 (4) 105 (4) 2 (3)
Sex, n (%)
   Male 1,006 (40) 996 (41) 10 (16)
   Female 1,481 (60) 1,430 (59) 51 (84)
Smoking status, n (%)
   Never 1,599 (64) 1,551 (64) 48 (79)
   Former 567 (23) 559 (23) 8 (13)
   Current 321 (13) 316 (13) 5 (8)
Respiratory disease, n (%) 2,487 (100) 2,426 (97.5) 61 (2.5)
   COPD (J44) 52 (100) 48 (92.3) 4 (7.7)
   Bronchial asthma (J45) 772 (100) 754 (97.7) 18 (2.3)
   Pulmonary emphysema (J43) 127 (100) 121 (95.3) 6 (4.7)
   Possible obstructive pulmonary disease** 53 (100) 52 (98.1) 1 (1.9)
   Other 1483 (100) 1451 (97.8) 32 (2.2)
Corticosteroid use, n (%) 263 (100) 253 (96.2) 10 (3.8) 
   Systemic use, plain, n (%) 51 (100) 48 (94.1) 3 (5.9)
   Inhalants, n (%) 203 (100) 196 (96.6) 7 (3.4)
   Corticosteroids in combination with adrenergics, n (%) 30 (100) 28 (93.3) 2 (6.7)
   Glucocorticoids, n (%) 173 (100) 168 (97.1) 5 (2.9)
   Not specified form, n (%) 9 (100) 9 (100) 0 (0)
*metabolic equivalent task (MET)-hours/day; **participants using inhalants (short or long acting b2 adrenergic and/or anticholinergics and/or corticosteroids) without 
ever having reported in the questionnaires “a doctor’s diagnosis” of respiratory disease
a wrong perception that inhaled corticosteroids 
are not “so bad” as systemic [28]. Thus, studies 
relating corticosteroids to fractures are important 
in order to persuade clinicians not to overtreat 
elderly patients.
The present study is nested in a large, well- 
-established cohort that is the EPIC-Greece cohort. 
The EPIC study recruited subjects using standar-
dized protocols and questionnaires. The study 
design substantially reduces the possibility of se-
lection bias. A main limitation of our study is the 
small number of participants with hip fractures 
during follow-up that did not allow us to reveal 
significant associations. However, we believe 
that the consistent increase we observed in hip 
fracture risk with corticosteroid intake, inhalants 
included, in all sub-analyses we performed (all 
participants, only participants with obstructive 
lung disease, only participants using corticoste-
roid inhalants) suggests possible association. 
Conclusion
Given the severe consequences of a hip 
fracture in the frail population of the elderly 
patients further studies are needed to determine 
the risk- benefit ratio of prescribing a medication 
of uncertain benefit such as corticosteroids to 
those suffering from chronic respiratory disease, 
COPD included. Moreover, specific guidelines 
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Table 2. Effect of corticosteroid use on hip fracture risk in respiratory patients compared to non-users (adjusting for age, 
sex, BMI, physical activity, educational level and smoking status)
Hip fracture
Hazard ratio 95% CI p
Corticosteroid intake (any form)
   Any respiratory disease 1.68 0.85–3.34 0.138
   Obstructive lung disease* 1.40 0.64–3.06 0.406
Corticosteroid intake (inhalants- R03AK, R03AK06, R03AK07, R03BA)
   Any respiratory disease 1.58 0.71–3.50 0.260
   Obstructive lung disease* 1.29 0.54–3.10 0.570
*COPD (J44), bronchial asthma (J45), pulmonary emphysema (J43) and participants using inhalants (short or long acting b2 adrenergic and/or anticholinergics and/ 
/or corticosteroids) without ever having reported in the questionnaires “a doctor’s diagnosis” of respiratory disease 
should be implemented for screening and treating 
osteoporosis in this population. 
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